Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
31 Oktober 2025
High bar for material adverse change in M&A: Lessons from the Mayne Pharma / Cosette decision
18 September 2025
Are you cyber ready? The cyber challenge through the eyes of Australia’s legal leaders
12 September 2025
Trump administration moves to rein in direct-to-consumer prescription drug advertising
21 Juli 2025
The UPC – Two years on
21 Juli 2025
No rest for the caretakers: health care industry in crosshairs for expanded False Claims Act and criminal enforcement activity
30 Juni 2025
New merger control regime – What you need to know for dealmaking in Australia
18 Juni 2025
Protecting your business: The implications of Australia’s new privacy tort
16 Mai 2025
Focus on minimum award rates and addressing gender undervaluation – which sectors are next?
6 Mai 2025
Australian Federal Election 2025 Wrap-Up – What businesses should expect for employment and industrial relations reform
23 April 2025
Managing challenges with SPVs on PFI projects
23 April 2025
Australian Federal Election 2025: Employment policies
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane